Search Result
Results for "
toxin conjugate
" in MedChemExpress (MCE) Product Catalog:
-
- HY-138298
-
|
T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
-
- HY-138298A
-
|
T-DXd; DS-8201; DS-8201a
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
-
- HY-132162
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
-
- HY-128915
-
|
|
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
Duocarmycin DM free base, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .
|
-
-
- HY-147340
-
|
Tirumotecan
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
|
-
-
- HY-147340A
-
|
Tirumotecan TFA
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
|
-
-
- HY-125586
-
|
|
DNA/RNA Synthesis
ADC Payload
|
Cancer
|
|
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
-
- HY-131089
-
|
|
DNA/RNA Synthesis
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-VC-PABC-C6-α-Amanitin is a Drug-Linker Conjugates for ADC, consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a MC-VC-PABC-C6 linker. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα.
|
-
-
- HY-153069
-
-
-
- HY-126690
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
-
- HY-159072
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
|
-
-
- HY-160807
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
|
-
-
- HY-15581
-
|
Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10
|
Microtubule/Tubulin
ADC Payload
|
Cancer
|
|
MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
|
-
-
- HY-126686
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.
|
-
-
- HY-W591408
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
|
-
-
- HY-128873
-
|
|
ADC Payload
DNA Alkylator/Crosslinker
|
Cancer
|
|
Duocarmycin GA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-agent resistant cell lines.
|
-
-
- HY-145622
-
|
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
|
Antibody-Drug Conjugates (ADCs)
TAM Receptor
|
Cancer
|
|
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .
|
-
-
- HY-132162A
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
-
- HY-130978
-
|
|
DNA Alkylator/Crosslinker
ADC Payload
|
Cancer
|
|
Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .
|
-
-
- HY-176774
-
|
|
Toll-like Receptor (TLR)
NF-κB
|
Cancer
|
|
L07-2 is a TLR7/8 agonist. L07-2 is a linker-toxin building block that can be used to synthesize immunostimulatory antibody conjugates (ISACs) for cancer research. L07-2 can be used to studies related to tumors such as non-small cell lung cancer .
|
-
-
- HY-164088
-
-
-
- HY-78932A
-
|
|
ADC Linker
|
Cancer
|
|
Dap-NE hydrochloride is a dipeptide hydrochloride and a cleavable ADC Linker.Dap-NE hydrochloride can be used to connect Antibody and toxin molecules (Cytotoxin) to synthesize Antibody-Drug Conjugates (ADCs) .
|
-
-
- HY-168317
-
-
-
- HY-148380
-
-
-
- HY-171489
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. Mal-VC-PAB-EDA-N-Ac-Calicheamicin consists of ADC toxin Calicheamicin (HY-19609) and a linker. Mal-VC-PAB-EDA-N-Ac-Calicheamicin can be used for synthesis of ADC, PF-06647263 (HY-111965) .
|
-
-
- HY-178219
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
|
-
-
- HY-107770
-
|
|
ADC Payload
DNA Alkylator/Crosslinker
|
Cancer
|
|
Duocarmycin MB is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MB can be used against multi-agent resistant cell lines.
|
-
-
- HY-18987
-
|
|
ADC Payload
DNA Alkylator/Crosslinker
|
Cancer
|
|
Duocarmycin MA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-agent resistant cell lines.
|
-
-
- HY-148380A
-
-
-
- HY-164303
-
-
-
- HY-178489
-
|
|
Nectin-4
|
Cancer
|
|
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
|
-
-
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
-
-
- HY-132162B
-
|
|
ADC Payload
|
Cancer
|
|
7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
|
-
-
- HY-128979B
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
|
-
-
- HY-153069A
-
-
-
- HY-128880
-
-
-
- HY-128881
-
-
-
- HY-136291
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Sulfo-SPDB-DGN462 is a agent-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).
|
-
-
- HY-176526
-
|
|
Drug Intermediate
Btk
|
Cancer
|
|
BTK degrader-1 intermediate (compound 5) is an intermediate for the synthesis of BTK degrader-1 (HY-163295). BTK degrader-1 can be used as an ADC toxin to synthesize antibody-drug conjugate (ADC) .
|
-
-
- HY-176415S
-
|
|
Isotope-Labeled Compounds
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
|
-
-
- HY-161780
-
|
|
Drug-Linker Conjugates for ADC
CDK
|
Cancer
|
|
Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules .
|
-
-
- HY-153236
-
-
-
- HY-182972
-
|
|
Drug-Linker Conjugates for ADC
JAK
|
Inflammation/Immunology
Cancer
|
|
Mal-PEG4-NPV-PABC-DMEDA-tofacitinib is a conjugate of a toxin and a linker, consisting of the JAK inhibitor Tofacitinib (HY-40354) and the linker Mal-PEG4-NPV-PABC-DMEDA (HY-182977). Mal-PEG4-NPV-PABC-DMEDA-tofacitinib can be used for the synthesis of ADC molecules .
|
-
-
- HY-179327
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
N-(Hexanoyloxy)succinimide-MMAE is a conjugate of the ADC drug toxin molecule and the linker, containing a degradable PEG linker and the toxin molecule MMAE (HY-15162) .
|
-
-
- HY-181958
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
mAb-AsnAsn-E104 is a conjugate of an ADC drug toxin molecule and a linker, which contains a degradable PEG linker and the toxin molecule E104 (HY-156174) .
|
-
-
- HY-182805
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
6-Dehydroxy-demethylation-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal is a conjugate of the ADC drug toxin molecule and the linker, containing a degradable PEG linker and the toxin molecule I-4, a bicyclic peptide derived from amatoxin .
|
-
-
- HY-185569
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
DM21-L-G NHS ester is a toxin molecule-linker conjugate that can be used for the synthesis of ADCs, such as Opugotamig olatansine (HY-185427) .
|
-
-
- HY-160969
-
|
|
ADC Payload
|
Cancer
|
|
DUBA is a toxin compound that acts on DNA, exhibiting alkylating activity. DUBA is an ADC payload that can be coupled with monoclonal antibodies to synthesize antibody-drug conjugates (ADCs) .
|
-
-
- HY-182806
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
Demethylation-desulfuration-α-Amanitin-OH-PAB-Ala-Val-CO-C2-mal is a conjugate of an ADC drug toxin molecule and a linker, containing a degradable PEG linker and the toxin molecule M-4, which is a cyclic peptide derived from α-Amanitin (HY-19610) .
|
-
-
- HY-185495
-
|
|
ADC Linker
|
Cancer
|
|
seco-CBI-PBD-disulfide linker is a conjugate of an ADC drug toxin molecule and a linker, consisting of two potent DNA-damaging moieties seco-CBI, PBD (HY-101127), and a disulfide linker .
|
-
- HY-178279
-
|
|
Drug-Linker Conjugates for ADC
|
Others
|
|
Mc-Gly-Gly-Phe-Gly-PAB-pSar11-Exatecan (compound L-D-5) is a toxin-linker compound that can be used for the preparation of antibody-drug conjugates (ADCs) .
|
-
- HY-185492
-
-
- HY-181184
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-GGFG-3-Methylenecyclobutyl-Exatecan (Raludotatug-L-1-1) is a conjugate of the toxin molecule Exatecan (HY-13631) and the linker (HY-181185), and it can be used for the synthesis of ADC molecules .
|
-
- HY-183558
-
-
- HY-176415S1
-
|
Cys-MC-GGFG-Dxd-d5 TFA
|
Isotope-Labeled Compounds
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
|
-
- HY-P992488
-
|
ZV0501 Antibody
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
|
-
-
- HY-138298
-
|
T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
|
蛍光色素
|
|
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-138298A
-
|
T-DXd; DS-8201; DS-8201a
|
蛍光色素
|
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
|
-
- HY-145622
-
|
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
|
蛍光色素
|
|
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .
|
-
- HY-125586
-
|
|
DNA/RNA Synthesis
ADC Payload
|
Cancer
|
|
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
- HY-178489
-
|
|
Nectin-4
|
Cancer
|
|
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
|
-
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
| 製品番号 |
製品名 |
Target |
研究分野 |
Image |
-
- HY-P992488
-
|
ZV0501 Antibody
|
Transmembrane Glycoprotein
ADC Antibody
|
Cancer
|
|
ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
|
-
(5)
-
- HY-176415S
-
|
|
|
Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research .
|
-
-
- HY-176415S1
-
|
|
|
Cys-MC-GGFG-Dxd-d5 TFA (Cys-MC-GGFG-Dxd-d5 TFA) is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd-d5 TFA is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd-d5 TFA is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd-d5 TFA can be used in cancer research .
|
-
-
- HY-126690
-
|
|
|
DBCO
|
|
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate . DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-W591408
-
|
|
|
DBCO
|
|
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
|
入力情報は安全に管理されます. ※ 必須入力項目.
Inquiry Information
- 製品名:
- 製品番号:
- 数量:
- MCE 日本正規代理店:
